Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2017
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Gastric cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer
- Focus Adverse reactions; Pharmacokinetics
- 20 Feb 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 16 Feb 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.